{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:10:03Z","timestamp":1790359803222,"version":"4.1.0"},"reference-count":37,"publisher":"Portland Press Ltd.","issue":"4","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,8,1]]},"abstract":"<jats:p>JAK (Janus kinase) 2 plays a critical role in signal transduction through several cytokine receptors. JAKs contain a typical tyrosine kinase domain preceded by a pseudokinase [JH2 (JAK homology 2)] domain which has been considered to be catalytically inactive. Identification of activating mutations in the JH2 domain of JAK2 as the major cause for polycythaemia vera and other MPNs (myeloproliferative neoplasms) demonstrate the critical regulatory function for this domain, but the underlying mechanisms have remained elusive. We have performed biochemical and functional analysis on the JH2 domain of JAK2. The results indicate that JH2 functions as an active protein kinase and phosphorylates two residues in JAK2 (Ser523 and Tyr570) that have been shown previously to be negative regulatory sites for JAK2 activity. The crystal structure of the JAK2 JH2 domain provides an explanation for the functional findings and shows that JH2 adopts a prototypical kinase fold, but binds MgATP through a non-canonical mode. The structure of the most prevalent pathogenic JH2 mutation V617F shows a high level of similarity to wild-type JH2. The most notable structural deviation is observed in the N-lobe \u03b1C-helix. The structural and biochemical data together with MD (molecular dynamics) simulations show that the V617F mutation rigidifies the \u03b1C-helix, which results in hyperactivation of the JH1 domain through an as yet unidentified mechanism. These results provide structural and functional insights into the normal and pathogenic function of the JH2 domain of JAK2.<\/jats:p>","DOI":"10.1042\/bst20130005","type":"journal-article","created":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T08:50:01Z","timestamp":1374137401000},"page":"1002-1007","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["New insights into the structure and function of the pseudokinase domain in JAK2"],"prefix":"10.1042","volume":"41","author":[{"given":"Olli","family":"Silvennoinen","sequence":"first","affiliation":[{"name":"School of Medicine and Institute of Biomedical Technology, University of Tampere, 33014 Tampere, Finland"},{"name":"Department of Internal Medicine, Tampere University Hospital, 33520 Tampere, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Ungureanu","sequence":"additional","affiliation":[{"name":"School of Medicine and Institute of Biomedical Technology, University of Tampere, 33014 Tampere, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashavanthi","family":"Niranjan","sequence":"additional","affiliation":[{"name":"School of Medicine and Institute of Biomedical Technology, University of Tampere, 33014 Tampere, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Hammaren","sequence":"additional","affiliation":[{"name":"School of Medicine and Institute of Biomedical Technology, University of Tampere, 33014 Tampere, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajintha","family":"Bandaranayake","sequence":"additional","affiliation":[{"name":"Structural Biology Program, Kimmel Center for Biology and Medicine of the Skirball Institute, Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, 540 First Avenue, New York, NY 10016, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stevan\u00a0R.","family":"Hubbard","sequence":"additional","affiliation":[{"name":"Structural Biology Program, Kimmel Center for Biology and Medicine of the Skirball Institute, Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, 540 First Avenue, New York, NY 10016, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2013,7,18]]},"reference":[{"key":"2021111818052485700_B1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.iy.13.040195.002101","article-title":"Signaling through the hematopoietic cytokine receptors","volume":"13","author":"Ihle","year":"1995","journal-title":"Annu. Rev. Immunol."},{"key":"2021111818052485700_B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0161-5890(00)00018-3","article-title":"The Jak\u2013STAT pathway","volume":"37","author":"Imada","year":"2000","journal-title":"Mol. Immunol."},{"key":"2021111818052485700_B3","doi-asserted-by":"crossref","first-page":"8429","DOI":"10.1073\/pnas.90.18.8429","article-title":"Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction","volume":"90","author":"Silvennoinen","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111818052485700_B4","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1097-2765(01)00398-7","article-title":"Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases","volume":"8","author":"Zhou","year":"2001","journal-title":"Mol. Cell"},{"key":"2021111818052485700_B5","doi-asserted-by":"crossref","first-page":"998","DOI":"10.4049\/jimmunol.180.2.998","article-title":"Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation","volume":"180","author":"Haan","year":"2008","journal-title":"J. Immunol."},{"key":"2021111818052485700_B6","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/BF02981953","article-title":"Negative regulators of cytokine signaling","volume":"73","author":"Kile","year":"2001","journal-title":"Int. J. Hematol."},{"key":"2021111818052485700_B7","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1128\/MCB.24.11.4968-4978.2004","article-title":"Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling","volume":"24","author":"Feener","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"2021111818052485700_B8","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1128\/MCB.01589-05","article-title":"Phosphorylation of Jak2 on Ser523 inhibits Jak2-dependent leptin receptor signaling","volume":"26","author":"Ishida-Takahashi","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"2021111818052485700_B9","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1128\/MCB.00278-09","article-title":"Regulation of Jak2 function by phosphorylation of Tyr317 and Tyr637 during cytokine signaling","volume":"29","author":"Robertson","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"2021111818052485700_B10","doi-asserted-by":"crossref","first-page":"47954","DOI":"10.1074\/jbc.M205156200","article-title":"The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction","volume":"277","author":"Saharinen","year":"2002","journal-title":"J. Biol. Chem."},{"key":"2021111818052485700_B11","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.bbrc.2004.10.071","article-title":"Determination of the transphosphorylation sites of Jak2 kinase","volume":"325","author":"Matsuda","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021111818052485700_B12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0092-8674(00)81168-X","article-title":"Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis","volume":"93","author":"Neubauer","year":"1998","journal-title":"Cell"},{"key":"2021111818052485700_B13","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1128\/MCB.24.11.4955-4967.2004","article-title":"Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity","volume":"24","author":"Argetsinger","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"2021111818052485700_B14","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1210\/me.2009-0355","article-title":"Tyrosines 868, 966, and 972 in the kinase domain of JAK2 are autophosphorylated and required for maximal JAK2 kinase activity","volume":"24","author":"Argetsinger","year":"2010","journal-title":"Mol. Endocrinol."},{"key":"2021111818052485700_B15","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1128\/MCB.01591-05","article-title":"Phosphorylation of JAK2 at serine 523: a negative regulator of JAK2 that is stimulated by growth hormone and epidermal growth factor","volume":"26","author":"Mazurkiewicz-Munoz","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"2021111818052485700_B16","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.1038\/sj.emboj.7601365","article-title":"Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2","volume":"25","author":"Funakoshi-Tago","year":"2006","journal-title":"EMBO J."},{"key":"2021111818052485700_B17","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1128\/MCB.24.10.4557-4570.2004","article-title":"Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-B\u03b2","volume":"24","author":"Kurzer","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"2021111818052485700_B18","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1074-7613(00)00054-6","article-title":"Partial impairment of cytokine responses in Tyk2-deficient mice","volume":"13","author":"Karaghiosoff","year":"2000","journal-title":"Immunity"},{"key":"2021111818052485700_B19","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1074-7613(00)00055-8","article-title":"Tyk2 plays a restricted role in IFN\u03b1 signaling, although it is required for IL-12-mediated T cell function","volume":"13","author":"Shimoda","year":"2000","journal-title":"Immunity"},{"key":"2021111818052485700_B20","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1128\/MCB.20.10.3387-3395.2000","article-title":"Regulation of the Jak2 tyrosine kinase by its pseudokinase domain","volume":"20","author":"Saharinen","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"2021111818052485700_B21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF00279527","article-title":"The Drosophila tumorous-lethal hematopoietic oncogene is a dominant mutation in the hopscotch locus","volume":"238","author":"Hanratty","year":"1993","journal-title":"Mol. Gen. Genet."},{"key":"2021111818052485700_B22","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.270.5237.797","article-title":"Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development","volume":"270","author":"Russell","year":"1995","journal-title":"Science"},{"key":"2021111818052485700_B23","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"2021111818052485700_B24","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.molmed.2005.10.003","article-title":"A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects","volume":"11","author":"James","year":"2005","journal-title":"Trends Mol. Med."},{"key":"2021111818052485700_B25","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"2021111818052485700_B26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"2021111818052485700_B27","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nsmb.2099","article-title":"The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling","volume":"18","author":"Ungureanu","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2021111818052485700_B28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pep.2009.09.011","article-title":"Expression, purification, characterization and crystallization of non- and phosphorylated states of JAK2 and JAK3 kinase domain","volume":"69","author":"Hall","year":"2010","journal-title":"Protein Expression Purif."},{"key":"2021111818052485700_B29","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2141.2007.06806.x","article-title":"Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera","volume":"139","author":"Scott","year":"2007","journal-title":"Br. J. Haematol."},{"key":"2021111818052485700_B30","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/S0140-6736(08)61341-0","article-title":"Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome","volume":"372","author":"Bercovich","year":"2008","journal-title":"Lancet"},{"key":"2021111818052485700_B31","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nsmb.2348","article-title":"Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F","volume":"19","author":"Bandaranayake","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2021111818052485700_B32","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1182\/blood-2005-02-0707","article-title":"Crystal structure of the Jak3 kinase domain in complex with a staurosporine analogue","volume":"106","author":"Boggon","year":"2005","journal-title":"Blood"},{"key":"2021111818052485700_B33","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1021\/jm101157q","article-title":"Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family","volume":"54","author":"Thoma","year":"2011","journal-title":"J. Med. Chem."},{"key":"2021111818052485700_B34","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jmb.2009.01.041","article-title":"Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains","volume":"387","author":"Williams","year":"2009","journal-title":"J. Mol. Biol."},{"key":"2021111818052485700_B35","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/blood-2005-06-2413","article-title":"The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor","volume":"107","author":"Lucet","year":"2006","journal-title":"Blood"},{"key":"2021111818052485700_B36","doi-asserted-by":"crossref","first-page":"21608","DOI":"10.1073\/pnas.0912101106","article-title":"Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3","volume":"106","author":"Jura","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111818052485700_B37","doi-asserted-by":"crossref","first-page":"7692","DOI":"10.1073\/pnas.1002753107","article-title":"ErbB3\/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation","volume":"107","author":"Shi","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."}],"container-title":["Biochemical Society Transactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/41\/4\/1002\/724851\/bst0411002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/41\/4\/1002\/724851\/bst0411002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T13:22:09Z","timestamp":1637241729000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article\/41\/4\/1002\/67144\/New-insights-into-the-structure-and-function-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,18]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,7,18]]},"published-print":{"date-parts":[[2013,8,1]]}},"URL":"https:\/\/doi.org\/10.1042\/bst20130005","relation":{},"ISSN":["0300-5127","1470-8752"],"issn-type":[{"value":"0300-5127","type":"print"},{"value":"1470-8752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,18]]}}}